[8-K] Air Industries Group Reports Material Event
Stoke Therapeutics, Inc. (Nasdaq: STOK) filed a Form 8-K on July 10, 2025 under Item 7.01 (Regulation FD). The filing states that the company issued a press release (Exhibit 99.1) announcing the presentation of data from an analysis that informed the design of the planned Phase 3 EMPEROR study and evaluated the potential effects of the proposed zorevunersen dosing regimen. No financial metrics, study results, or timelines were included in the 8-K. The information is furnished (not filed) and therefore is not incorporated by reference into other Exchange Act or Securities Act filings unless specifically stated.
Stoke Therapeutics, Inc. (Nasdaq: STOK) ha presentato un modulo 8-K il 10 luglio 2025 ai sensi della voce 7.01 (Regolamento FD). Nel documento si comunica che la societ脿 ha rilasciato un comunicato stampa (Allegato 99.1) in cui annuncia la presentazione dei dati di un'analisi che ha guidato la progettazione dello studio di Fase 3 EMPEROR pianificato e ha valutato i potenziali effetti del regime posologico proposto per zorevunersen. Nel modulo 8-K non sono stati inclusi dati finanziari, risultati dello studio o tempistiche. Le informazioni sono fornite (e non depositate) e pertanto non sono incorporate per riferimento in altri documenti ai sensi dell'Exchange Act o del Securities Act, salvo diversa indicazione.
Stoke Therapeutics, Inc. (Nasdaq: STOK) present贸 un Formulario 8-K el 10 de julio de 2025 bajo el 铆tem 7.01 (Regulaci贸n FD). El documento indica que la compa帽铆a emiti贸 un comunicado de prensa (Exhibici贸n 99.1) anunciando la presentaci贸n de datos de un an谩lisis que inform贸 el dise帽o del estudio de Fase 3 EMPEROR planeado y evalu贸 los posibles efectos del r茅gimen de dosificaci贸n propuesto para zorevunersen. No se incluyeron m茅tricas financieras, resultados del estudio ni cronogramas en el 8-K. La informaci贸n se proporciona (no se presenta formalmente) y, por lo tanto, no se incorpora por referencia en otros documentos bajo la Exchange Act o Securities Act, a menos que se indique espec铆ficamente.
Stoke Therapeutics, Inc. (雮橃姢雼�: STOK)電� 2025雲� 7鞗� 10鞚� 頃 7.01(Regulation FD)鞐� 霐半澕 Form 8-K毳� 鞝滌稖頄堨姷雼堧嫟. 鞝滌稖 氍胳劀鞐愲姅 須岇偓臧� 氤挫“ 氍胳劀 99.1搿� 氤挫澊電� 氤措弰鞛愲毳� 氚滍憸頄堨溂氅�, 鞚措姅 瓿勴殟霅� 3靸� EMPEROR 鞐瓣惮 靹り硠毳� 鞎岆Μ電� 攵勳劃 雿办澊韯办檧 鞝滌晥霅� zorevunersen 韴棳 鞖旊矔鞚� 鞛犾灛鞝� 鞓來枼鞚� 韽夑皜頃� 雮挫毄鞛勳潉 氇呾嫓頃橁碃 鞛堨姷雼堧嫟. 8-K鞐愲姅 鞛 歆�響�, 鞐瓣惮 瓴瓣臣 霕愲姅 鞚检爼鞚� 韽暔霅橃 鞎婌晿鞀惦媹雼�. 鞚� 鞝曤炒電� 鞝滌稖霅� 瓴冹澊 鞎勲媽 鞝滉车霅� 鞝曤炒搿滌劀, 韸闺硠頌� 氇呾嫓霅橃 鞎婋姅 頃� 雼るジ Exchange Act 霕愲姅 Securities Act 氍胳劀鞐� 彀胳“搿� 韽暔霅橃 鞎婌姷雼堧嫟.
Stoke Therapeutics, Inc. (Nasdaq : STOK) a d茅pos茅 un formulaire 8-K le 10 juillet 2025 sous l'item 7.01 (R猫glement FD). Le d茅p么t indique que la soci茅t茅 a publi茅 un communiqu茅 de presse (Exhibit 99.1) annon莽ant la pr茅sentation de donn茅es issues d'une analyse qui a orient茅 la conception de l'茅tude de phase 3 EMPEROR pr茅vue et 茅valu茅 les effets potentiels du sch茅ma posologique propos茅 pour le zorevunersen. Aucun indicateur financier, r茅sultat d'茅tude ou calendrier n鈥檃 茅t茅 inclus dans le 8-K. Les informations sont fournies (et non d茅pos茅es) et ne sont donc pas incorpor茅es par r茅f茅rence dans d'autres d茅p么ts relevant de l'Exchange Act ou du Securities Act, sauf indication contraire explicite.
Stoke Therapeutics, Inc. (Nasdaq: STOK) reichte am 10. Juli 2025 ein Formular 8-K unter Punkt 7.01 (Regulation FD) ein. Die Einreichung besagt, dass das Unternehmen eine Pressemitteilung (Anlage 99.1) ver枚ffentlicht hat, in der die Pr盲sentation von Daten aus einer Analyse angek眉ndigt wird, die das Design der geplanten Phase-3-EMPEROR-Studie informierte und die potenziellen Auswirkungen des vorgeschlagenen Dosierungsschemas f眉r Zorevunersen bewertete. Finanzkennzahlen, Studienergebnisse oder Zeitpl盲ne wurden im 8-K nicht enthalten. Die Informationen werden bereitgestellt (nicht eingereicht) und sind daher nicht in andere Einreichungen nach dem Exchange Act oder Securities Act durch Verweis aufgenommen, sofern nicht ausdr眉cklich angegeben.
- None.
- None.
Insights
TL;DR: Routine Reg FD update; provides visibility on Phase 3 planning but lacks efficacy or financial data.
The 8-K simply notifies investors that Stoke has released supportive data used to shape its upcoming Phase 3 EMPEROR trial of zorevunersen. Because the document omits the data itself, it offers limited incremental insight into clinical risk or valuation. The disclosure is furnished under Item 7.01, signalling that management views it as informational rather than materially transformative. Absent study results or new guidance, I classify the immediate market impact as neutral.
Stoke Therapeutics, Inc. (Nasdaq: STOK) ha presentato un modulo 8-K il 10 luglio 2025 ai sensi della voce 7.01 (Regolamento FD). Nel documento si comunica che la societ脿 ha rilasciato un comunicato stampa (Allegato 99.1) in cui annuncia la presentazione dei dati di un'analisi che ha guidato la progettazione dello studio di Fase 3 EMPEROR pianificato e ha valutato i potenziali effetti del regime posologico proposto per zorevunersen. Nel modulo 8-K non sono stati inclusi dati finanziari, risultati dello studio o tempistiche. Le informazioni sono fornite (e non depositate) e pertanto non sono incorporate per riferimento in altri documenti ai sensi dell'Exchange Act o del Securities Act, salvo diversa indicazione.
Stoke Therapeutics, Inc. (Nasdaq: STOK) present贸 un Formulario 8-K el 10 de julio de 2025 bajo el 铆tem 7.01 (Regulaci贸n FD). El documento indica que la compa帽铆a emiti贸 un comunicado de prensa (Exhibici贸n 99.1) anunciando la presentaci贸n de datos de un an谩lisis que inform贸 el dise帽o del estudio de Fase 3 EMPEROR planeado y evalu贸 los posibles efectos del r茅gimen de dosificaci贸n propuesto para zorevunersen. No se incluyeron m茅tricas financieras, resultados del estudio ni cronogramas en el 8-K. La informaci贸n se proporciona (no se presenta formalmente) y, por lo tanto, no se incorpora por referencia en otros documentos bajo la Exchange Act o Securities Act, a menos que se indique espec铆ficamente.
Stoke Therapeutics, Inc. (雮橃姢雼�: STOK)電� 2025雲� 7鞗� 10鞚� 頃 7.01(Regulation FD)鞐� 霐半澕 Form 8-K毳� 鞝滌稖頄堨姷雼堧嫟. 鞝滌稖 氍胳劀鞐愲姅 須岇偓臧� 氤挫“ 氍胳劀 99.1搿� 氤挫澊電� 氤措弰鞛愲毳� 氚滍憸頄堨溂氅�, 鞚措姅 瓿勴殟霅� 3靸� EMPEROR 鞐瓣惮 靹り硠毳� 鞎岆Μ電� 攵勳劃 雿办澊韯办檧 鞝滌晥霅� zorevunersen 韴棳 鞖旊矔鞚� 鞛犾灛鞝� 鞓來枼鞚� 韽夑皜頃� 雮挫毄鞛勳潉 氇呾嫓頃橁碃 鞛堨姷雼堧嫟. 8-K鞐愲姅 鞛 歆�響�, 鞐瓣惮 瓴瓣臣 霕愲姅 鞚检爼鞚� 韽暔霅橃 鞎婌晿鞀惦媹雼�. 鞚� 鞝曤炒電� 鞝滌稖霅� 瓴冹澊 鞎勲媽 鞝滉车霅� 鞝曤炒搿滌劀, 韸闺硠頌� 氇呾嫓霅橃 鞎婋姅 頃� 雼るジ Exchange Act 霕愲姅 Securities Act 氍胳劀鞐� 彀胳“搿� 韽暔霅橃 鞎婌姷雼堧嫟.
Stoke Therapeutics, Inc. (Nasdaq : STOK) a d茅pos茅 un formulaire 8-K le 10 juillet 2025 sous l'item 7.01 (R猫glement FD). Le d茅p么t indique que la soci茅t茅 a publi茅 un communiqu茅 de presse (Exhibit 99.1) annon莽ant la pr茅sentation de donn茅es issues d'une analyse qui a orient茅 la conception de l'茅tude de phase 3 EMPEROR pr茅vue et 茅valu茅 les effets potentiels du sch茅ma posologique propos茅 pour le zorevunersen. Aucun indicateur financier, r茅sultat d'茅tude ou calendrier n鈥檃 茅t茅 inclus dans le 8-K. Les informations sont fournies (et non d茅pos茅es) et ne sont donc pas incorpor茅es par r茅f茅rence dans d'autres d茅p么ts relevant de l'Exchange Act ou du Securities Act, sauf indication contraire explicite.
Stoke Therapeutics, Inc. (Nasdaq: STOK) reichte am 10. Juli 2025 ein Formular 8-K unter Punkt 7.01 (Regulation FD) ein. Die Einreichung besagt, dass das Unternehmen eine Pressemitteilung (Anlage 99.1) ver枚ffentlicht hat, in der die Pr盲sentation von Daten aus einer Analyse angek眉ndigt wird, die das Design der geplanten Phase-3-EMPEROR-Studie informierte und die potenziellen Auswirkungen des vorgeschlagenen Dosierungsschemas f眉r Zorevunersen bewertete. Finanzkennzahlen, Studienergebnisse oder Zeitpl盲ne wurden im 8-K nicht enthalten. Die Informationen werden bereitgestellt (nicht eingereicht) und sind daher nicht in andere Einreichungen nach dem Exchange Act oder Securities Act durch Verweis aufgenommen, sofern nicht ausdr眉cklich angegeben.
FAQ
What did Stoke Therapeutics (STOK) announce in its July 10, 2025 Form 8-K?
Does the 8-K include actual results from the Phase 3 EMPEROR study?
Is the information in Exhibit 99.1 considered "filed" with the SEC?
Were any financial statements or earnings figures provided in this 8-K?
What is the trading symbol and exchange listing for Stoke Therapeutics?
